Spots Global Cancer Trial Database for combination
Every month we try and update this database with for combination cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Dose Finding Study for Combination of Capecitabine, Lapatinib and Vinorelbine in Metastatic Breast Cancer | NCT01238029 | Metastatic Brea... HER2 Positive First or Second... Failure or Cont... | Lapatinib and C... | 18 Years - | Sponsor GmbH | |
| A Phase I Trial of Abraxane, Cisplatin and 5-Fluorouracil Along With Chemoradiotherapy in Advanced Head and Neck Cancer | NCT00731380 | Head and Neck C... | ABI-007 | 18 Years - | University Health Network, Toronto | |
| Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma | NCT01023308 | Multiple Myelom... | Panobinostat Bortezomib Dexamethasone Placebo | 18 Years - | Novartis | |
| A Study Of Neratinib (HKI-272) And Capecitabine In Japanese With Solid Tumor | NCT01128842 | Advanced Malign... | Neratinib Capecitabine | 20 Years - | Puma Biotechnology, Inc. | |
| Study on the Efficacy of LAS41005 in the Treatment of Actinic Keratosis | NCT00987246 | Actinic Keratos... | Placebo Gel LAS41005 LAS106521 | 18 Years - 85 Years | Almirall, S.A. | |
| BT062 in Combination With Lenalidomide or Pomalidomide and Dexamethasone in Patients With Multiple Myeloma | NCT01638936 | Multiple Myelom... | BT062 , intrave... | 18 Years - | Biotest Pharmaceuticals Corporation | |
| Dose Finding Study for Combination of Capecitabine, Lapatinib and Vinorelbine in Metastatic Breast Cancer | NCT01238029 | Metastatic Brea... HER2 Positive First or Second... Failure or Cont... | Lapatinib and C... | 18 Years - | Sponsor GmbH | |
| A Study of PSB205 in Subjects With Advanced Solid Tumors | NCT03986606 | Neoplasm Malign... | PSB205 | 18 Years - | Qilu Puget Sound Biotherapeutics (dba Sound Biologics) | |
| Study Evaluating Safety And Tolerability, Solid Tumor | NCT00768469 | Advanced Malign... | Neratinib Paclitaxel | 20 Years - | Puma Biotechnology, Inc. | |
| Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and Paclitaxel | NCT04449549 | Neoplasms | Nilotinib and P... | 18 Years - 120 Years | National Institutes of Health Clinical Center (CC) | |
| Dabrafenib and Trametinib for BRAF-inhibitor Pretreated Patients | NCT02296996 | Malignant Melan... | Dabrafenib + Tr... | 18 Years - | Universitair Ziekenhuis Brussel | |
| A Phase II Randomized, Double-blind, Placebo-controlled Study of Sorafenib or Placebo in Combination With Transarterial Chemoembolization (TACE) Performed With DC Bead and Doxorubicin for Intermediate Stage Hepatocellular Carcinoma (HCC). | NCT00855218 | Carcinoma, Hepa... | Sorafenib (Nexa... Placebo | 18 Years - | Bayer | |
| Safety Study of LBH589 When Given in Combination With Bortezomib in Adult Patients With Multiple Myeloma | NCT00532389 | Multiple Myelom... | LBH589 | 18 Years - | Novartis | |
| Safety Study of LBH589 When Given in Combination With Lenalidomide and Dexamethasone in Adult Patients With Multiple Myeloma. | NCT00532675 | Multiple Myelom... | LBH589 Lenalidomide | 18 Years - | Novartis | |
| Trial of PI-88 With Dacarbazine in Patients With Metastatic Melanoma | NCT00130442 | Melanoma | PI-88 and dacar... dacarbazine or ... | 18 Years - | Cellxpert Biotechnology Corp. | |
| Safety and Efficiency of γδ T Cell Against Breast Cancer(Her-, er-, and pr-) | NCT02418481 | Breast Cancer | DC-CIK γδ T Cell Combination | 18 Years - 75 Years | Fuda Cancer Hospital, Guangzhou | |
| Gemcitabine (GFF) in Patients With Pancreatic Cancer | NCT00919282 | Metastatic Panc... | gemcitabine, fo... | 18 Years - | CONKO-Studiengruppe | |
| A Study of Elacytarabine (CP-4055) Plus Idarubicin as Second Course Remission-Induction Therapy in Patients With Acute Myeloid Leukaemia | NCT01035502 | Acute Myeloid L... | Elacytarabine p... | 18 Years - | Clavis Pharma | |
| A Study of PSB205 in Subjects With Advanced Solid Tumors | NCT03986606 | Neoplasm Malign... | PSB205 | 18 Years - | Qilu Puget Sound Biotherapeutics (dba Sound Biologics) | |
| Randomized Trial of ATN-224 and Temozolomide in Advanced Melanoma | NCT00383851 | Melanoma | ATN-224 Temozolomide | 18 Years - | Attenuon | |
| BT062 in Combination With Lenalidomide or Pomalidomide and Dexamethasone in Patients With Multiple Myeloma | NCT01638936 | Multiple Myelom... | BT062 , intrave... | 18 Years - | Biotest Pharmaceuticals Corporation | |
| Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma | NCT01023308 | Multiple Myelom... | Panobinostat Bortezomib Dexamethasone Placebo | 18 Years - | Novartis | |
| AZD2281 in Combination With Liposomal Doxorubicin in Advanced Solid Tumours | NCT00819221 | Solid Tumors | AZD2281 liposomal doxor... | 18 Years - 130 Years | AstraZeneca | |
| A Phase I Trial of Abraxane, Cisplatin and 5-Fluorouracil Along With Chemoradiotherapy in Advanced Head and Neck Cancer | NCT00731380 | Head and Neck C... | ABI-007 | 18 Years - | University Health Network, Toronto | |
| Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and Paclitaxel | NCT04449549 | Neoplasms | Nilotinib and P... | 18 Years - 120 Years | National Institutes of Health Clinical Center (CC) | |
| Elderly NSCLC/D vs DP (JCOG0207) | NCT00190476 | Non-small-cell ... | Weekly docetaxe... Weekly docetaxe... | 70 Years - | Japan Clinical Oncology Group | |
| Safety and Efficacy of Fludarabine and Cyclophosphamide + Rituximab | NCT00393107 | Follicular Lymp... | rituximab rituximab,fluda... | 18 Years - 70 Years | Gruppo Italiano Studio Linfomi | |
| Cetuximab Plus P-HDFL for the First-line Treatment of Advanced Gastric Cancer | NCT00275951 | Gastric Cancer | Cetuximab Plus ... | 18 Years - 75 Years | National Taiwan University Hospital | |
| Erlotinib in Combination With Select Tyrosine Kinase Inhibitors in Adult Patients With Advanced Solid Tumors | NCT06161558 | Neoplasms | Erlotinib Lenvatinib Axitinib | 18 Years - 120 Years | National Institutes of Health Clinical Center (CC) | |
| Trial of PI-88 With Docetaxel in Advanced Non-Small-Cell Lung Cancer (NSCLC) | NCT00097851 | Carcinoma, Non-... | docetaxel PI-88 | 18 Years - | Cellxpert Biotechnology Corp. | |
| Safety Study of LBH589 When Given in Combination With Bortezomib in Adult Patients With Multiple Myeloma | NCT00532389 | Multiple Myelom... | LBH589 | 18 Years - | Novartis | |
| Ketoconazole Plus Docetaxel to Treat Prostate Cancer | NCT00032825 | Prostatic Neopl... | Ketaconazole Docetaxel | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Safety Study of LBH589 When Given in Combination With Lenalidomide and Dexamethasone in Adult Patients With Multiple Myeloma. | NCT00532675 | Multiple Myelom... | LBH589 Lenalidomide | 18 Years - | Novartis | |
| PROCLAIM-CX-072: A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas | NCT03013491 | Solid Tumor Lymphoma | CX-072 ipilimumab vemurafenib | 18 Years - | CytomX Therapeutics | |
| Dabrafenib and Trametinib for BRAF-inhibitor Pretreated Patients | NCT02296996 | Malignant Melan... | Dabrafenib + Tr... | 18 Years - | Universitair Ziekenhuis Brussel | |
| Determining the Maximum Tolerated Dose of Low Dose Interferon-alpha in Conjunction With Nilotinib in Pretreated Philadelphia Chromosome Positive (Ph+) Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP) | NCT01220648 | Chronic Myeloid... | Nilotinib, inte... | 18 Years - | Novartis | |
| Study Evaluating Safety And Tolerability, Solid Tumor | NCT00768469 | Advanced Malign... | Neratinib Paclitaxel | 20 Years - | Puma Biotechnology, Inc. | |
| Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma | NCT01023308 | Multiple Myelom... | Panobinostat Bortezomib Dexamethasone Placebo | 18 Years - | Novartis | |
| First-line Combination Treatment Based on Anlotinib | NCT03628521 | Lung Cancer Advanced Stage | Anlotinib，Erlot... | 18 Years - 75 Years | Shanghai Chest Hospital | |
| Ketoconazole Plus Docetaxel to Treat Prostate Cancer | NCT00032825 | Prostatic Neopl... | Ketaconazole Docetaxel | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Ketoconazole Plus Docetaxel to Treat Prostate Cancer | NCT00032825 | Prostatic Neopl... | Ketaconazole Docetaxel | 18 Years - | National Institutes of Health Clinical Center (CC) |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
